|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, we conducted this research to examine the therapeutic effects of nicotinamide against hepatocellular carcinoma (HCC) both in vivo and in vitro through affecting IGF-1 and the balance between PKB and Nrf2.
|
30784932 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
While AKT2 is the major isoform downstream of activated phosphoinositide 3-kinase and loss of phosphatase and tensin homolog-induced HCC, the precise function of AKT1 in hepatocarcinogenesis is largely unknown.
|
31062368 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Also, AKT2 was increased in HCC tissues.
|
31802908 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Whereas combined Akt1 and Akt2 rapidly induced mortality, hepatic Akt inhibition induced liver injury that promotes hepatocellular carcinoma.
|
28557977 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, AKT2 was identified as a novel direct and functional target of miR‑296‑5p in HCC.
|
28586057 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, possible crosstalk between CDC42 and another miR-137 target gene, AKT2, was evaluated by co-overexpressing CDC42 and AKT2 in the HuH7 and MHCC97L cells and examining their effects on miR-137-mediated HCC regulation. miR-137 was confirmed to be downregulated in the HCC cell lines.
|
26352279 |
2015 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our previous study identified AKT1, AKT2 and AKT3 as unfavorable prognostic factors for patients with hepatocellular carcinoma (HCC).
|
25424347 |
2014 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Together, our findings indicate that miR-137 is a valuable biomarker for HCC prognosis and the FoxD3/miR-137/AKT2 regulatory network plays an important role in HCC progression.
|
24970808 |
2014 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Further experimental validation also indicated that AKT1, AKT2 and AKT3 proteins may all be novel unfavorable prognostic factors for patients with HCC.
|
24247267 |
2014 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Importantly, silencing AKT2 recapitulated the cellular and molecular effects seen upon miR-302b overexpression, which included inhibiting hepatocellular carcinoma cell proliferation, suppressing G1 regulators (Cyclin A, Cyclin D1, CDK2) and increasing p27Kip1 phosphorylation at Ser10.
|
24337067 |
2014 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
Crosstalk between PTEN/Akt2 and TGFbeta signaling involving EGF receptor down-regulation during the tumor promotion process from the early stage in a rat two-stage hepatocarcinogenesis model.
|
19309364 |
2009 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
Our findings suggest that Akt2, but not Akt1, is a novel independent predictor for the development and progression of HCC.
|
14654898 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways.
|
12361705 |
2002 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The modulation of GnT-V activity by signaling molecules in PI-3-K/PKB pathway in human hepatocarcinoma cell line 7721 was studied.
|
11261840 |
2000 |